Full article: Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis
![PDF] Increased CA 19-9 level in patients without malignant disease | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/26d5394683ead29cd4fea31dc58ad39515b843a6/3-Table1-1.png "PDF] Increased CA 19-9 level in patients without malignant disease | Semantic Scholar")
PDF] Increased CA 19-9 level in patients without malignant disease | Semantic Scholar
![PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a96fc01f495907ea18214fdc7db7ffd9b210d72c/2-TableI-1.png "PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar")
PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar
The prognostic and predictive value of serum CA19.9 in pancreatic cancer - ScienceDirect
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients | Scientific Reports
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
Tumor Markers:- Part 7 - CA 125 and CA 19-9 - Labpedia.net
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer - Yang - Journal of Gastrointestinal Oncology
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer - Yang - Journal of Gastrointestinal Oncology
PDF) Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Cancers | Free Full-Text | Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in Gastrointestinal Cancers: Biological Rationale towards a Personalized Clinical Application
Cancers | Free Full-Text | Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in Gastrointestinal Cancers: Biological Rationale towards a Personalized Clinical Application
The prognostic and predictive value of serum CA19.9 in pancreatic cancer - ScienceDirect
CA 19–9 predicts resectability of pancreatic cancer even in jaundiced patients - ScienceDirect
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy?
